Welcome to our dedicated page for CRTX news (Ticker: CRTX), a resource for investors and traders seeking the latest updates and insights on CRTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRTX's position in the market.
Cortexyme, Inc. (NASDAQ: CRTX) announced a partial clinical hold from the FDA on its atuzaginstat (COR388) due to hepatic adverse events. This affects the open-label extension phase of the GAIN Trial, halting new enrollments and discontinuing current participants. However, the ongoing double-blind study with 643 participants will continue. Cortexyme emphasized participant safety and aims for top-line results in Q4 2021. The GAIN Trial evaluates atuzaginstat's efficacy in mild to moderate Alzheimer’s disease, exploring its impact on periodontal disease as well.
Cortexyme, Inc. (Nasdaq: CRTX) announced key leadership appointments aimed at enhancing operations and advancing its Alzheimer’s drug, atuzaginstat. Chris Lowe has been promoted to COO and CFO, while Ted Monohon becomes Chief Accounting Officer. Drew Sukovich joins as Vice President of Regulatory and Quality. These changes coincide with Cortexyme's ambition to reach critical milestones in 2021, including data readouts in Alzheimer’s and periodontal disease. The company remains focused on proving the connection between gingipains and degenerative diseases.
Cortexyme, Inc. (Nasdaq: CRTX) recently provided a corporate update, showcasing significant achievements in 2020 and outlining key milestones for 2021. The company exceeded its enrollment target in the pivotal GAIN Trial for Alzheimer's disease and completed an interim analysis in December 2020. Key upcoming milestones include data readouts for atuzaginstat in Alzheimer’s and periodontal diseases expected in Q4 2021, and the initiation of the PEAK Trial for Parkinson’s disease in Q3 2021. Cortexyme's cash reserves are projected to support operations through 2023.
Cortexyme, Inc. (Nasdaq: CRTX) announced that the Data Monitoring Committee recommended continuing the Phase 2/3 GAIN Trial of atuzaginstat (COR388) after an interim analysis of approximately 300 patients. The trial aims to evaluate atuzaginstat's efficacy in treating mild to moderate Alzheimer’s disease, with topline data expected in December 2021. The analysis assessed various factors including safety and potential efficacy, and found no concerns for futility or overwhelming efficacy. Cortexyme remains focused on addressing Alzheimer's with its investigational treatment.
Cortexyme, Inc. (Nasdaq: CRTX) announced its Q3 2020 financial results, reporting a net loss of $21.5 million or $0.73 per share. The company is advancing its Phase 2/3 GAIN Trial for atuzaginstat, exceeding its enrollment target with 643 participants. The interim analysis is expected in December 2020. Cortexyme holds $197.9 million in cash, anticipated to fund operations into 2022. Recent research highlights a strong correlation between P. gingivalis and Alzheimer's, underpinning the trial’s design and objectives.
Cortexyme, Inc. (Nasdaq: CRTX) announced its forthcoming presentations at notable scientific conferences. At the Clinical Trials on Alzheimer's Disease Digital Event (CTAD 2020), an oral presentation will focus on the ongoing Phase 2/3 GAIN Trial assessing atuzaginstat in over 570 patients with mild to moderate Alzheimer’s disease. The trial targets toxic proteases linked to Alzheimer’s. Additionally, a poster presentation at the Society for Immunotherapy of Cancer’s Annual Meeting will explore the effect of gingipain inhibitors on cancer immune evasion. Key dates include November 5th and 9th.